Tech Session V: Nanomedicine and Nanoscale Delivery (Focus: Oral)
Oral delivery of MSC-EVs as a novel approach to treat inflammatory bowel disease
Thursday, July 17, 2025
11:05 AM – 11:16 AM EDT
Introduction: Inflammatory bowel disease (IBD) is a chronic and incurable inflammatory condition of the gastrointestinal tract, which affects over 10 million people worldwide (1). Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are promising novel therapeutics for IBD due to their regenerative and immunomodulatory properties. However, MSC-EVs are administered by injection and there is a need to explore alternative routes of delivery which could offer advantages over systemic delivery, such as the oral route which is more convenient and can directly target the site of action in IBD.
Learning Objectives:
At the completion of this activity, participants will know
Define MSC-EVs
Understand the regenerative and anti-inflammatory properties of MSC-EVs
Explain how the double coating formulation protects MSC-EVs from GI degradation and target the colon
